Evommune, Inc. (EVMN)

Evommune Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Net Income	-64.76	-68.31	-34.05
Depreciation & Amortization	1.44	1.29	1
Share-Based Compensation	-	1.72	1.48
Other Operating Activities	-31.53	5.6	1.6
Operating Cash Flow	-94.85	-58.2	-29.97
Capital Expenditures	0	-0.09	-0.12
Change in Investments	-	-3.91	-48.32
Investing Cash Flow	7.83	-3.99	-48.43
Share Issuance / Repurchase	-	49.84	63.98
Debt Issued / Paid	-	-0.42	-0.23
Financing Cash Flow	113.78	49.42	63.75
Net Cash Flow	26.76	-12.77	-14.65
Free Cash Flow	-94.85	-58.28	-30.09
Free Cash Flow Margin	-3161.53%	-832.61%	-601.76%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).